Home
overview

Encompassing an industry-led agenda including academic keynote presentations, SMi's 9th annual conference on Imaging in Cancer Drug Development will be a unique opportunity to witness presentations on the current developments surrounding: oncology and diagnostic imaging modalities, drug development and clinical development alongside networking with key industry professionals.


This leading event will provide attendees with a complete view of the field and will focus primarily on oncology imaging modalities and applications in pre-clinical case studies, clinical imaging applications and innovations in imaging technology. This highly informative event will bring together key opinion leaders in the field to provide attendees with a comprehensive look into current advances in oncology imaging.


This year's agenda offers an unmatched opportunity for debate and resolution of key challenges currently facing the field. This will encourage attendees to discuss growth in the field and exchange ideas, therefore driving the field forward and ensuring sufficient treatment of the key issues surrounding oncology imaging and drug development.


 

  • Evaluate the expansion of medical imaging products currently in the market
  • Discover the latest innovations in software platforms and diagnostic solutions
  • Build strategic partnerships with experts in the field
  • Understand the cost containment programmes in key markets
  • Explore standardisation and development of proficiency in the field

 New for 2013:


• Balance of pre-clinical and clinical imaging modalities
• Spotlight on imaging biomarkers for efficient prognosis
• Considering multi-faceted datasets

 

This event is unmissable for Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in:


• Imaging and Translational Medicine
• Molecular Imaging
• Cancer Research
• Oncology
• Pre-clinical Imaging
• Clinical Imaging
• PET Research
• Biomarkers
• Target Discovery
• Pharmacokinetics/Pharmacodynamics
• Drug Discovery & Design
• Computer-Aided Drug Design
• Computational Chemistry
• Structure and Informatics
• Molecular Interaction
• Medical Imaging
• Clinical Pharmacology
• Biophysics
• Screening
• Clinical Development
• Structural Biology


 

Abbott Laboratories; ABX-CRO; AstraZeneca; Bayer Schering Pharma; BioClinica; Biomedical Systems; Biomedical Systems Europe; Biospace Lab; Bracco Imaging Spa; BTG; Cancer Research UK; Clinical and Experimental Pharmacology Paterson Institute for Cancer Research University of Manchester; Clinical Imaging Centre - Glaxo Smith Kline; CoreLabPartners; Cosmix Molecular Biologicals; Cronus Technologies; Daiichi Sankyo CO LTD; EORTC; F. Hoffmann-La Roche; GlaxoSmithKline; GSK; ICON Development Solutions; ICON Medical Imaging; Imagingequipment; Imanova; Imperial College London; InfoGoSoft; Institute of Cancer Research; iThera Medical; Kings College; LEO Pharma; MEDIAN Technologies; Medicines & Healthcare Products Regulatory Agency (MHRA) ; Merck; MHRA; Miltenyi Biotech Inc; nanoPET Pharma GmbH; Newcastle University; NHS Innovations London ; Novartis International AG; Oncology Pharma Ltd; Orion Pharma; Perceptive Informatics; Poznan University of Medical Sciences; Roche Diagnostics; Teva Pharmaceuticals Ltd; TNO Pharma; U T M D Anderson Cancer Center; UCL; UCL Cancer Institute; UCL Centre for Advanced Biomedical Imaging; Vision Healthcare Consultancy Ltd; VU University Medical Center;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Peter Eggleton

Peter Eggleton, Medical Director, Merck

9:10 Application of in vivo and ex vivo imaging in the drug development process: monitoring primary tumor growth, metastasis and angiogenesis

Werner Scheuer

Werner Scheuer, Research Leader Preclinical Imaging; Pharma Research and Early Development, Roche Diagnostics

  • Application of fluorescence and bioluminescence for drug monitoring in xenografts
  • Monitoring primary tumor growth, metastasis and angiogenesis
  • Simultaneous measurement of pharmacodynamics and pharmacokinetics
  • Future aspects (Cerenkov and hybrid systems)
  • 9:50 Novel advances in molecular imaging using the PhotonIMAGER OPTIMA system

    Serge Maitrejean

    Serge Maitrejean, Director of R&D, Biospace Lab

  • Novel targets
  • Compare and contrast analogues
  • Challenges faced with novel targets
  • Future developments
  • 10:30 Morning Refreshments

    11:00 Non-invasive imaging of pre-clinical models for basic translational research

    Francois Lassailly

    Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK

  • Whole body optical imaging (bioluminescence and NIR fluorescence), X-ray micro CT and Multiphoton intravital microscopy
  • Strengths and limitations
  • Ongoing developments
  • 11:40 Overcoming chemical challenges in Radiotracer development

    Erik  Arstad

    Erik Arstad, Senior Lecturer in Radiochemistry, UCL Cancer Institute

  • Synthesis of dual optical and nuclear tracers for multiscale imaging
  • Preparation of functional nanoparticles for imaging with SPECT and MRI
  • One-pot ‘click-labelling’ of chemically labile precursors
  • 18F aromatic labelling of ‘drug-like’ tracers
  • 12:20 Networking Lunch

    13:40 Imaging tumour treatment response using hyperpolarised 13C magnetic resonance spectroscopic imaging

    Kevin Brindle

    Kevin Brindle, Professor of Biomedical Magnetic Resonance, University of Cambridge and Cancer Research UK

  • Changes in tumour size are a poor indicator of response
  • Has the drug hit its target
  • Has the drug killed any tumours cells
  • Imaging the tumour microenvironment - redox state and pH
  • 14:20 Current role of PET/CT in cancer imaging – hybrid imaging improves the assessment of bone metastasis

    Yong Du

    Yong Du, Consultant in Nuclear Medicine and PET/CT, The Royal Marsden

  • The skeleton is a common site for metastases and newer treatment are under investigation
  • Bone metastases are usually considered “non-measurable” 
  • Hybrid imaging provides new insight in the assessment of bone metastases
  • 15:00 Afternoon Tea

    15:30 Novel cancer drug development approaches using medical imaging modalities

    Kurt Anderson

    Kurt Anderson, Research Group Leader, The Beatson Institute For Cancer Research

    16:10 Central review of progression free survival – is this the beginning of the end?

    Prash  Krishna

    Prash Krishna, Director - Oncology, Clinical Development, Eisai

  • History of IRC; current practice and impact on costs
  • ODAC on IRC alternatives: Background, Methods and Discussion
  • Feasibility of an IRC audit to assess bias in INV, a viable and cost-effectice alternative
  • The road ahead (Furture of IRC in Oncology)...?
  • 16:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Janos  Kriston-Vizi

    Janos Kriston-Vizi, Group Leader of Bioinformatics Image Core, MRC

    9:10 PET/SPECT imaging biomarker development

    Bert Windhorst

    Bert Windhorst, Head Radiopharmaceutical Chemistry, VU University Medical Centre

  • Target identification and lead finding
  • Radiochemistry aspects
  • Preclinical evaluation
  • Translation towards clinic
  • 9:50 Applications of urinary metabolic profiling

    Jane Cox

    Jane Cox, Senior Research Scientist, Foundation for Liver Research

  • Urinary metabolic biomarkers of hepatocellular carcinoma
  • Examples of urinary profiling of drug-induced hepatoxicity
  • Biomarkers and translational magnetic resonance spectroscopy
  • 10:30 Morning Refreshments

    11:00 Novel agents for PET imaging of cancer

    Laura Kenny

    Laura Kenny, Clinical Senior Lecturer/Consultant in Medical Oncology, Imperial College

     

  • Role of Imaging Biomarkers in Cancer
  • Proliferation
  • Angiogenesis
  • Apoptosis
  • 11:40 Imaging modalities in drug discovery: high-content screening of a kinase inhibitor small molecule library to identify autophagy regulators

    Janos  Kriston-Vizi

    Janos Kriston-Vizi, Group Leader of Bioinformatics Image Core, MRC

  • Primary cellular screen in a human lung cancer monolayer
  • Confirmatory screen, concentration series to generate dose-response curve
  • 3D spheroid culture dose-response screen
  • 12:20 Networking Lunch

    13:40 Outmanagement for imaging experts in cancer drug development

  • Practical tools for survival and growth during a period of retrenchment
  • Expansion of medical imaging products in the market
  • Managing practical issues associated with oncology imaging
  • Standardization and development of proficiency in the field
  • Peter Eggleton

    Peter Eggleton, Medical Director, Merck

    David Eggleton

    David Eggleton, Department of Management, Sussex University

    14:20 The pricing and reimbursement environment

    Brian Lovatt

    Brian Lovatt, Managing Director & Chief Executive, Vision Healthcare Consultancy Ltd

  • Key changes to payers willingness to pay
  • The cost containment programmes in key markets
  • How to ‘prove’ value
  • 15:00 Panel Discussion: Clinical application and innovation of imaging modalities

    Peter Eggleton

    Peter Eggleton, Medical Director, Merck

    Erik  Arstad

    Erik Arstad, Senior Lecturer in Radiochemistry, UCL Cancer Institute

    Yong Du

    Yong Du, Consultant in Nuclear Medicine and PET/CT, The Royal Marsden

    Bert Windhorst

    Bert Windhorst, Head Radiopharmaceutical Chemistry, VU University Medical Centre

    15:40 Afternoon Tea

    16:10 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Bert Windhorst

    Bert Windhorst

    Head Radiopharmaceutical Chemistry, VU University Medical Centre
    Francois Lassailly

    Francois Lassailly

    In-vivo Imaging Specialist, Cancer Research UK
    Peter Eggleton

    Peter Eggleton

    Medical Director, Merck
    Prash  Krishna

    Prash Krishna

    Director - Oncology, Clinical Development, Eisai
    Werner Scheuer

    Werner Scheuer

    Research Leader Preclinical Imaging; Pharma Research and Early Development, Roche Diagnostics

    Bert Windhorst

    Head Radiopharmaceutical Chemistry, VU University Medical Centre
    Bert Windhorst

    Brian Lovatt

    Managing Director & Chief Executive, Vision Healthcare Consultancy Ltd
    Brian Lovatt

    David Eggleton

    Department of Management, Sussex University
    David Eggleton

    Erik Arstad

    Senior Lecturer in Radiochemistry, UCL Cancer Institute
    Erik  Arstad

    Francois Lassailly

    In-vivo Imaging Specialist, Cancer Research UK
    Francois Lassailly

    Jane Cox

    Senior Research Scientist, Foundation for Liver Research
    Jane Cox

    Janos Kriston-Vizi

    Group Leader of Bioinformatics Image Core, MRC
    Janos  Kriston-Vizi

    Kevin Brindle

    Professor of Biomedical Magnetic Resonance, University of Cambridge and Cancer Research UK
    Kevin Brindle

    Kurt Anderson

    Research Group Leader, The Beatson Institute For Cancer Research
    Kurt Anderson

    Laura Kenny

    Clinical Senior Lecturer/Consultant in Medical Oncology, Imperial College
    Laura Kenny

    Peter Eggleton

    Medical Director, Merck
    Peter Eggleton

    Prash Krishna

    Director - Oncology, Clinical Development, Eisai
    Prash  Krishna

    Serge Maitrejean

    Director of R&D, Biospace Lab
    Serge Maitrejean

    Werner Scheuer

    Research Leader Preclinical Imaging; Pharma Research and Early Development, Roche Diagnostics
    Werner Scheuer

    Yong Du

    Consultant in Nuclear Medicine and PET/CT, The Royal Marsden
    Yong Du

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.